Curonix Receives the First Full-Body Peripheral Nerve Stimulator (PNS) FDA Clearance, including Craniofacial Pain Indication, for its Freedom® PNS System
09 juil. 2024 08h00 HE
|
Curonix LLC
Curonix Receives the First Full-Body Peripheral Nerve Stimulator (PNS) FDA Clearance, including Craniofacial Pain Indication, for its Freedom® PNS System.
Curonix Partners with Sure Med Compliance to Expand PNS Clinical Evidence
18 janv. 2024 08h00 HE
|
Curonix LLC
Curonix Partners with Sure Med Compliance to Expand PNS Clinical Evidence
Curonix Celebrates 1st Anniversary
01 nov. 2023 09h00 HE
|
Curonix LLC
POMPANO BEACH, Fla., Nov. 01, 2023 (GLOBE NEWSWIRE) -- Today, Curonix LLC, a leading peripheral nerve stimulation company celebrated its first anniversary. In November 2022, Curonix completed the...
Pain Management Devices Market Set to Soar to USD 9.4 Billion by 2032 || 8.1% CAGR - Opine Market.us Analysts
10 oct. 2023 09h34 HE
|
Market.Us
New York, Oct. 10, 2023 (GLOBE NEWSWIRE) -- According to Market.us, the Pain Management Devices Market size is expected to be worth around USD 9.4 Billion by 2032 from USD 4.4 Billion in 2022,...
Independent clinical study shows Curonix’s Freedom® PNS System significantly reduces pain scores and medication usage
07 juin 2023 07h00 HE
|
Curonix LLC
POMPANO BEACH, Fla., June 07, 2023 (GLOBE NEWSWIRE) -- Curonix LLC, a medical technology company dedicated to freeing patients from chronic pain, announced the publication of 24 months of data from...
Venodol Roll-on, Spotlight Innovation's New Analgesic Product, Now Available at Amazon.com
11 janv. 2018 08h30 HE
|
Spotlight Innovation Inc.
URBANDALE, IA, Jan. 11, 2018 (GLOBE NEWSWIRE) -- Spotlight Innovation Inc. (OTCQB: STLT), a pharmaceutical company targeting rare, emerging and neglected diseases, today announced that Company...